https://www.mynewsdesk.com/de/certmedica Mynewsdesk RSS - Pressemitteilungen, Nachrichten und Blogeinträge. https://www.mynewsdesk.com/de/certmedica https://www.mynewsdesk.com/assets/graphics/logos/logo-small-9892f98564f91864075bd14001f8470f2f9bf254729c37044b4b1ac9b0db6b40.png 128 23 de 15 Mon, 04 May 2026 14:42:16 +0200 A https://www.mynewsdesk.com/de/certmedica/blog_posts/certmedica-bringt-die-my-formoline-app-auf-den-markt-121397?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/blog_posts/certmedica-bringt-die-my-formoline-app-auf-den-markt-121397?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH Thu, 29 Jan 2026 14:30:00 +0100 Mit formoline Intervall 5:2 führt Certmedica eine anwenderzentrierte Behandlungseinheit für das Gewichtsmanagement ein. Die Kombipackung aus dem Medizinprodukt formoline L112 und formoline mannan unterstützt gezielt die Umsetzung des 5:2-Intervallfastens, verbessert die Alltagstauglichkeit und fördert Adhärenz sowie langfristige Compliance durch klare Struktur und evidenzbasierte Wirkprinzipien. https://www.mynewsdesk.com/de/certmedica/pressreleases/intervallfasten-neu-gedacht-mit-formoline-intervall-5-2-3429551?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/pressreleases/intervallfasten-neu-gedacht-mit-formoline-intervall-5-2-3429551?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH Thu, 29 Jan 2026 14:30:00 +0100 With formoline Interval 5:2, Certmedica introduces a user-centered treatment unit for weight management. The combination of the medical devices formoline L112 and formoline mannan supports the implementation of 5:2 intermittent fasting, improves everyday usability, and promotes adherence and long-term compliance through a clear structure and evidence-based principles. https://www.mynewsdesk.com/de/certmedica/pressreleases/intermittent-fasting-reimagined-with-formoline-intervall-5-2-3429580?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/pressreleases/intermittent-fasting-reimagined-with-formoline-intervall-5-2-3429580?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH Wed, 15 Oct 2025 15:36:15 +0200 https://www.mynewsdesk.com/de/certmedica/news/improvement-of-metabolic-syndrome-with-formoline-l112-502213?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/news/improvement-of-metabolic-syndrome-with-formoline-l112-502213?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH Wed, 15 Oct 2025 09:00:29 +0200 https://www.mynewsdesk.com/de/certmedica/news/verbesserung-des-metabolischen-syndroms-mit-formoline-l112-502108?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/news/verbesserung-des-metabolischen-syndroms-mit-formoline-l112-502108?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH Wed, 15 Oct 2025 09:00:00 +0200 https://www.mynewsdesk.com/de/certmedica/news/improvement-of-metabolic-syndrome-with-formoline-l112-502116?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/news/improvement-of-metabolic-syndrome-with-formoline-l112-502116?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH Thu, 08 May 2025 18:59:02 +0200 Mehr Behandlungserfolg mit Liporeform protect: Viele Patienten scheitern an dauerhaften Lebensstiländerungen. Liporeform protect unterstützt hier gezielt: Der patentierte Ballaststoff Polyglucosamin bindet schädliche Fette im Darm, senkt nachweislich LDL-Cholesterin und Triglyceride und fördert die Gewichtsabnahme – klinisch belegt. https://www.mynewsdesk.com/de/certmedica/news/cholesterinsenkung-fuer-die-naturheilpraxis-496982?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/news/cholesterinsenkung-fuer-die-naturheilpraxis-496982?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH Thu, 08 May 2025 18:54:11 +0200 Polyglucosamin ist ein wirksamer Lipidbinder mit LDL-senkendem Effekt. Liporeform protect reduziert erhöhte Blutfettwerte durch verminderte Fettresorption, was zu einer geringeren Energieaufnahme und klinisch relevanter Gewichtsabnahme führt. So kann sich der Gesundheitszustand bei Übergewichtigen verbessern. https://www.mynewsdesk.com/de/certmedica/news/information-fuer-fachkreise-liporeform-protect-497093?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/news/information-fuer-fachkreise-liporeform-protect-497093?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH Thu, 27 Mar 2025 14:27:10 +0100 Certmedica International hat die COFEPRIS-Zulassung für die formoline L112-Serie in Mexiko erhalten. Die Produkte (500 mg und 750 mg) sind Medizinprodukte der Klasse III zur Behandlung von Übergewicht und Adipositas. Angesichts hoher Adipositasraten bieten sie eine sichere Option zur Gewichtsreduktion und werden bis Mitte 2025 in über 6.000 Apotheken und Kliniken eingeführt. https://www.mynewsdesk.com/de/certmedica/pressreleases/certmedica-betritt-den-mexikanischen-markt-nach-cofepris-zulassung-fur-formoline-l112-als-medizinprodukt-der-klasse-iii-3377898?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/pressreleases/certmedica-betritt-den-mexikanischen-markt-nach-cofepris-zulassung-fur-formoline-l112-als-medizinprodukt-der-klasse-iii-3377898?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH Thu, 27 Mar 2025 14:24:20 +0100 Certmedica International has received COFEPRIS approval for its formoline L112 product series in Mexico, which includes two doses, 500 mg and 750 mg, classified as Class III medical devices for treating overweight and obesity. With Mexico's high obesity rates, the products offer a safe, effective weight-loss option, set for launch in over 6,000 pharmacies and clinics by mid-2025. https://www.mynewsdesk.com/de/certmedica/pressreleases/certmedica-enters-the-mexican-market-after-cofepris-approved-formoline-l112-as-class-iii-medical-device-3376912?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/pressreleases/certmedica-enters-the-mexican-market-after-cofepris-approved-formoline-l112-as-class-iii-medical-device-3376912?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH Fri, 28 Feb 2025 10:23:58 +0100 With the My-formoline app, Certmedica International GmbH is now providing an innovative digital solution that has been specially developed to support the intake of formoline L112, achieve weight goals, provide information about healthy eating and exercise and motivate people to lead a healthy lifestyle in the long term. https://www.mynewsdesk.com/de/certmedica/pressreleases/certmedica-supports-digital-weight-loss-with-my-formoline-app-3370830?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/pressreleases/certmedica-supports-digital-weight-loss-with-my-formoline-app-3370830?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH Fri, 28 Feb 2025 08:59:58 +0100 Mit der My-formoline App stellt die Certmedica International GmbH jetzt eine innovative digitale Lösung zur Verfügung, die speziell entwickelt wurde, um die Einnahme von formoline L112 zu unterstützen, Gewichtsziele zu erreichen, über gesunde Ernährung und Bewegung zu informieren und zu einem gesunden Lebensstiel langfristig zu motivieren. https://www.mynewsdesk.com/de/certmedica/pressreleases/certmedica-unterstutzt-abnehmen-digital-mit-der-my-formoline-app-3370828?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/pressreleases/certmedica-unterstutzt-abnehmen-digital-mit-der-my-formoline-app-3370828?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH Wed, 29 Jan 2025 00:00:00 +0100 https://www.mynewsdesk.com/de/certmedica/news/interview-with-certmedicas-coo-dr-marcus-furch-494214?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/news/interview-with-certmedicas-coo-dr-marcus-furch-494214?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH Fri, 24 Jan 2025 00:00:00 +0100 https://www.mynewsdesk.com/de/certmedica/news/abnehmen-in-den-wechseljahren-wohlfuehlfigur-ab-50-494208?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/news/abnehmen-in-den-wechseljahren-wohlfuehlfigur-ab-50-494208?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH Mon, 13 Jan 2025 00:00:00 +0100 https://www.mynewsdesk.com/de/certmedica/news/certmedica-exhibits-at-arab-health-2025-494210?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/news/certmedica-exhibits-at-arab-health-2025-494210?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH Thu, 24 Oct 2024 00:00:00 +0200 https://www.mynewsdesk.com/de/certmedica/news/das-metabolische-syndrom-abnehmen-und-gesuender-leben-494489?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/news/das-metabolische-syndrom-abnehmen-und-gesuender-leben-494489?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH Mon, 23 Sep 2024 00:00:00 +0200 https://www.mynewsdesk.com/de/certmedica/news/gewichtsreduktion-in-der-kinderwunschzeit-adipositas-und-kinderwunsch-494271?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/news/gewichtsreduktion-in-der-kinderwunschzeit-adipositas-und-kinderwunsch-494271?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH Wed, 24 Apr 2024 00:00:00 +0200 https://www.mynewsdesk.com/de/certmedica/news/gewichtsverlust-als-therapie-abnehmen-bei-bluthochdruck-494488?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/news/gewichtsverlust-als-therapie-abnehmen-bei-bluthochdruck-494488?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH Thu, 10 Aug 2023 00:00:00 +0200 https://www.mynewsdesk.com/de/certmedica/news/a-randomized-double-blind-placebo-controlled-clinical-study-to-evaluate-the-effect-on-the-weight-of-a-medical-device-with-polyglucosamine-l112-in-a-group-of-overweight-and-obese-subjects-494153?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/news/a-randomized-double-blind-placebo-controlled-clinical-study-to-evaluate-the-effect-on-the-weight-of-a-medical-device-with-polyglucosamine-l112-in-a-group-of-overweight-and-obese-subjects-494153?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH Thu, 11 Jan 2018 00:00:00 +0100 https://www.mynewsdesk.com/de/certmedica/news/influence-of-chitosan-treatment-on-surrogate-serum-markers-of-cholesterol-metabolism-in-obese-subjects-494167?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/de/certmedica/news/influence-of-chitosan-treatment-on-surrogate-serum-markers-of-cholesterol-metabolism-in-obese-subjects-494167?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Certmedica International GmbH